Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2015

View Archived Issues

PhaseBio presents data on diabetes candidates PE-0139 and PB-1023

First clinical results on mGluR5 tracer [18F]PSS-232

Bayer initiates phase III trial of copanlisib in rituximab-refractory indolent NHL

Novartis starts phase II trial of QBW-251 in COPD

Agalimmune licenses Kode Biotech's FSL technology for cancer immunotherapeutics

ONL Therapeutics advances photoreceptor protection programs for retinal diseases

Lipocine completes food effect study of oral testosterone LPCN-1021

New preclinical and phase I results presented for SNF-472 as an inhibitor of vascular calcification

First patient enrolled in phase II study of COL-1077 as an acute-use anesthetic

Amgen licenses Open Monoclonal Technology's OmniAb suite

OraSure Technologies receives BARDA funding to develop Ebola virus test

BioNTech's breast cancer diagnostic MammaTyper launched in Europe

Apexigen doses first patient in phase I trial of APX-005M

Reaction Biology receives grant to identify bromodomain modulators

PlantForm's anti-Ebola virus antibodies show neutralizing activity

FP-3-expressing oncolytic adenovirus shows potent antiangiogenic and antitumor efficacy

Pulmatrix and Mylan enter into an agreement for PUR-0200

Heron Therapeutics begins phase II trial of HTX-011 for postoperative pain

Incyte patents inhibitors of BET proteins

Genentech and Xenon disclose Nav1.7 channel blockers

Roche introduces PDE10A inhibitors

Bayer HealthCare and Johns Hopkins form retinal disease research alliance

Pharmascience patents inhibitors of protein kinases

Novogen introduces tropomyosin inhibitors

FDA awards fast track designation, clears phase IIb protocol for JVS-100 heart failure gene therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...